产品描述: | PD-166793是一种有效,选择性和具有口服活性的 MMP 的广谱抑制剂,对 MMP-2,MMP-3 和 MMP-13 表现出纳摩尔浓度的效价 (IC50=4,7,8 nM),对 MMP-1,-7 和 -9 表现出微摩尔的效价 (IC50=6.0,7.2,7.9 μM)。PD-166793 可以减轻进行性心力衰竭的大鼠模型中的左心室重构和功能障碍。 |
靶点: |
MMP-2:4 nM (IC50);MMP-3:7 nM (IC50);MMP |
体外研究: |
PD-166793 (0.1 μM) leads to a 20% inhibition of AMP deaminase (AMPD) activity in rat heart homogenates. PD-166793 (100 μM; 36 h) significantly reduces MMP‐9 activity in normal human cardiac fibroblasts. |
体内研究: |
PD-166793 (1 mg/kg/d; daily gavage for 10 weeks) largely prevents the adverse remodeling characteristically seen in the aortocaval (AV) fistula model. PD-166793 (5 mg/kg; oral gavage) exhibits superior pharmacokinetics (t1/2=43.6 h, Cmax=42.4 µg/mL, AUC0-∞=2822 µg•h/mL) in rats. |
参考文献: |
1. O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.
2. Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):24-37.
3. Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105(16):1983-8. |
溶解性: |
soluble in DMSO |
保存条件: |
-20℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
2.425 ml |
12.127 ml |
24.254 ml |
5 mM |
0.485 ml |
2.425 ml |
4.851 ml |
10 mM |
0.243 ml |
1.213 ml |
2.425 ml |
50 mM |
0.049 ml |
0.243 ml |
0.485 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |